Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)
Launched by ORGANON AND CO · Jun 23, 2008
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
Children, ages 2-11, with a history of perennial allergic rhinitis
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children patients of both sexes aged between 2-11 years, of either gender and any race
- • Unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation
- • Minimum score for inclusion: 10
- • Capable of complying with the dosing regimen
- • Free of any clinically significant disease (other than allergic rhinitis)
- • Antihistamine must be justified by investigating doctor
- Exclusion Criteria:
- • Patients with asthma who require chronic use of inhaled or systemic corticosteroids
- • History of frequent, clinically significant sinusitis or chronic purulent postnasal drip
- • Patients with rhinitis medicamentosa
- • History of hypersensitivity to desloratadine or any of its excipients
- • Doctor deems unsuitable
About Organon And Co
Organon & Co. is a global healthcare company dedicated to advancing women's health and improving patient outcomes through innovative therapies and solutions. With a strong focus on addressing unmet medical needs, Organon develops and commercializes a diverse portfolio of medicines, including reproductive health, contraception, and other critical areas affecting women's health. Committed to scientific excellence and collaboration, the company engages in clinical trials to explore new treatment avenues and enhance the quality of life for patients worldwide. Through its mission-driven approach, Organon strives to empower women and healthcare providers with the tools and resources necessary for informed decision-making and effective care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials